Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis

Rationale: The effectiveness and safety of aztreonam lysine for inhalation (AZLI) in patients with cystic fibrosis (CF) on maintenance treatment for Pseudomonasaeruginosa (PA)airway infection was evaluated in this randomized, double-blind, placebo-controlled study. Objectives: To evaluate the safety and efficacy of inhaled aztreonam lysine in controlling PA infection in patients with CF. Methods: After randomization and a 28-day course of tobramycin inhalationsolution (TIS),patients(n 5211; >6yr;>3TIScourseswithin previous year; FEV1 > 25% and